Neuronetics (STIM) to Release Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $29.07 million for the quarter.

Neuronetics Stock Performance

NASDAQ:STIM opened at $4.58 on Friday. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The firm has a market cap of $301.43 million, a PE ratio of -3.72 and a beta of 1.92. The firm has a 50 day simple moving average of $4.25 and a 200-day simple moving average of $2.71. Neuronetics has a 1-year low of $0.52 and a 1-year high of $5.92.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group increased their price target on Neuronetics from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th.

Insider Buying and Selling at Neuronetics

In related news, EVP William Andrew Macan sold 12,175 shares of the stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total value of $46,630.25. Following the transaction, the executive vice president now directly owns 388,647 shares of the company’s stock, valued at approximately $1,488,518.01. This trade represents a 3.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Stephen Furlong sold 14,836 shares of Neuronetics stock in a transaction on Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $48,662.08. Following the completion of the transaction, the chief financial officer now owns 482,572 shares in the company, valued at $1,582,836.16. The trade was a 2.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 100,369 shares of company stock worth $358,929 in the last 90 days. 8.70% of the stock is owned by company insiders.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.